Restriction of LABA use to combination ICS/LABA inhaler therapy in asthma

被引：7
|
作者：
Beasley, Richard [1 ,2 ]
Fingleton, James [1 ,2 ]
Weatherall, Mark [2 ,3 ]
机构：
[1] Med Res Inst New Zealand, Dept Internal Med, Wellington 6242, New Zealand
[2] Capital & Coast Dist Hlth Board, Dept Internal Med, Wellington, New Zealand
[3] Univ Otago Wellington, Dept Med, Wellington, New Zealand
来源：
THORAX | 2013年 / 68卷 / 02期
关键词：
RANDOMIZED CONTROLLED-TRIALS; FLUTICASONE PROPIONATE; EXTERNAL VALIDITY; SALMETEROL; CORTICOSTEROIDS; ADHERENCE; ADULTS; RISK; METAANALYSIS; MORTALITY;
D O I：
10.1136/thoraxjnl-2012-202483
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：119 / 120
页数：2
相关论文
共 50 条
  • [41] A randomized controlled trial of glycopyrrolate administered by metered dose inhaler in patients with uncontrolled asthma despite ICS/LABA treatment
    Kerwin, Edward
    Dorinsky, Paul
    Patel, Mehul
    Rossman, Kimberly
    Reisner, Colin
    Maes, Andrea
    Darken, Patrick
    Griffis, Dianne
    Fjallbrant, Harald
    JOURNAL OF ASTHMA, 2022, 59 (07) : 1420 - 1432
  • [42] Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma
    Richard Beasley
    James Harper
    Grace Bird
    Harriette Dunphy
    Alex Semprini
    Ian D. Pavord
    Alberto Papi
    Mark Weatherall
    BMC Pulmonary Medicine, 19
  • [43] CAPTAIN: Effects of age on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA
    Boulet, Louis-Philippe
    Lee, Laurie
    Kerstjens, Huib
    Papi, Alberto
    Zarankaite, Agne
    Pavord, Ian D.
    Bailes, Zelie
    Brusselle, Guy
    Barnes, Neil
    Hanania, Nicola A.
    Pascoe, Steven
    Oppenheimer, John
    Pizzichini, Emilio
    Fowler, Andrew
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [44] Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma
    Beasley, Richard
    Harper, James
    Bird, Grace
    Dunphy, Harriette
    Semprini, Alex
    Pavord, Ian D.
    Papi, Alberto
    Weatherall, Mark
    BMC PULMONARY MEDICINE, 2019, 19 (01)
  • [45] Predictors of treatment response to high-dose ICS/LABA or medium-dose ICS/LABA plus LAMA in asthma patients - TAILOR study
    Verhamme, K. M.
    De Ridder, M.
    Rijnbeek, P.
    Mosseveld, M.
    Pedersen, L.
    Marconi, E.
    Lapi, F.
    Tan, C.
    Delmestri, A.
    Prieto-Alhambra, D.
    Nudo, E.
    Brusselle, G.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60
  • [46] EFFECTIVENESS OF COPD MAINTENANCE THERAPY WITH LAMA/LABA VS LAMA/LABA/ICS IN A UNITED STATES CLAIMS DATABASE
    Quint, Jennifer
    Montonen, Jukka
    He, Xintong
    de la Hoz, Alberto
    Esposito, Daina
    CHEST, 2021, 160 (04) : 1863A - 1864A
  • [47] Cost effectiveness of umeclidinium bromide 62.5μg plus ICS/LABA versus ICS/LABA in COPD
    Driessen, Maurice
    Risebrough, Nancy
    Briggs, Andrew
    Ismaila, Afisi
    Shah, Dhvani
    Naya, Ian
    Baker, Timothy M.
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [48] High Healthcare Utilization in a Severe Asthma Population Despite Use of High Dose ICS/LABA
    Castro, M.
    Reaven, N.
    Funk, S.
    Jarjour, N.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [49] CONTINUOUS TREATMENT WITH FIXED COMBINATION OF LABA/ICS CAN AVOID COSTS OF HOSPITALIZATION IN ASTHMA AND COPD IN GERMANY
    Bonthapally, V
    Sindern, J.
    Wolbring, F.
    Mehnert, A.
    VALUE IN HEALTH, 2009, 12 (03) : A128 - A128
  • [50] Clinical-functional effectiveness of LABA plus ICS versus LABA plus ICS plus N-acetylcystein in severe bronchial asthma patients
    Yashyna, L.
    Gorovenko, N.
    Polianska, M.
    Moskalenko, S.
    ALLERGY, 2007, 62 : 213 - 213
12345